Table 1.
Participant Clinical and Laboratory Data
| HC (n = 106) | MDD (n = 90) | SCZ (n = 86) | P value | |
|---|---|---|---|---|
| Sex, female | 48 (45.3%) | 47 (52.2%) | 34 (39.5%) | .238a |
| Age (y) | 42.6 ± 15.4 (n = 106) | 43.7 ± 11.0 (n = 90) | 40.7 ± 10.4 (n = 86) | .365b |
| HAMD17-items score | 9.9 ± 8.2 (n = 77) | |||
| PANSS total score | 59.9 ± 15.6 (n = 78) | |||
| PANSS positive score | 13.9 ± 4.9 (n = 78) | |||
| PANSS negative score | 16.1 ± 5.2 (n = 78) | |||
| PANSS cognitive or general psychopathology score | 29.9 ± 8.6 (n = 78) | |||
| IMI-equivalent doses (mg/d) | 149.0 ± 131.7 (n = 47) | |||
| CPZ-equivalent doses (mg/d) | 86.8 ± 175.1 (n = 47) | 946.5 ± 950.8 (n = 61) | <.001c*** | |
| CSF levels of Glu (mg/dL) | 61.0 ± 10.7 (n = 104) | 61.5 ± 8.0 (n = 89) | 64.3 ± 14.1 (n = 86) | .112b |
| WCC (/mL) | 4.0 ± 3.0 (n = 104) | 4.2 ± 3.0 (n = 89) | 4.5 ± 4.1 (n = 86) | .660b |
Abbreviations: CPZ, chlorpromazine; Glu, glucose; HAMD, Hamilton Rating Scale for Depression; HC, healthy controls; IMI, imipramine; MDD, major depressive disorder; PANSS, Positive and Negative Syndrome Scale; SCZ, schizophrenia; WCC, white cell count.
Data shown as either mean ± SD and number or number and percent of total (%). ***P < .001.
aComparison between 3 groups by chi-squared test.
bComparison between 3 groups by the Kruskal Wallis test.
cComparison between 2 patients groups by the Mann-Whitney U-test.